Table 1.
SE Guideline Metrics Across the 4 Participating Sites
| Metrics | Site 1 | Site 2 | Site 3 | Site 4 |
|---|---|---|---|---|
| Stabilization Phase (0–5 min) | ||||
| 1. Vitals and oxygenation assessed | Y | Y | Y | Y |
| 2. Supplementary O2 initiated (facemask or nonrebreather) | N | N | N | Y |
| 3. Placed on continuous ECG monitor | Y | Y | Y | Y |
| 4. Collect finger stick blood glucose | N | N | N | Y |
| 5. Started timing seizure from onset | N | N | N | N |
| Initial Therapy Phase (5–20 min) | ||||
| 6. Time of 1st BZD administration | 10:15 | 6:32 | 2:40 | 2:15 |
| 7. BZD given | Ativan; Diazepam | Ativan | Ativan | Ativan |
| BZD route | Intravenous; Rectal | Intravenous | Intramuscular | Intramuscular |
| BZD dose (mg/kg) | 0.1; 0.5 | 0.1 | 0.2 | 0.1 |
| 8. Proper weight-based BZD dose | Y | Y | N | Y |
| 9. Repeat BZD dose × 1 if seizure continued after 3–5 minutes | Y | Y | Y | Y |
| Second Therapy Phase (20–40 min) | ||||
| 10. Use of recommended 2nd line agent | Y | Y | Y | Y |
| Second-line agent given | Levetiracetam | Levetiracetam | Fosphenytoin | Phenobarbital |
| Agent route | Intravenous | Intravenous | Intravenous | Intravenous |
| Agent dose (mg/kg) | 50 | 10 | 20 | 20 |
| 11. Proper weight-based ASM dose | Y | N | Y | Y |
| Third Therapy Phase | ||||
| 12. Team recognized need for anesthetic infusion, transfer to higher level of care | Y | Y | Y | Y |
| Composite score (/12) | 9/12 (75%) | 8/12 (67%) | 8/12 (67%) | 11/12 (92%) |
Notes: Actions either were or were not performed, denoted Y = yes and N = no. Composite score calculated as a sum of completed process measures out of 12 reported as a %.